Attovia Therapeutics, Inc.

NASDAQ:ATTO

Biotechnology

Healthcare
$15.53 -1.20%

-$0.18 today

Market cap
$709.92M
Beta
0.00
P/E (TTM)
-15.9
EPS (TTM)
-$0.86
52W Low $14.23High $28.00

Volume 0.34M

Average 0.45M

ATTO Interest Expense

Cost of servicing the company's debt during the period.

Attovia Therapeutics, Inc.NASDAQ: ATTO

Interest Expense · Q2 FY2026 · quarter ended Jun 2026

Interest expense of $0 in Q2 FY2026

Q2 FY2026 interest expense was $0.

Context

  • Interest expense amounted to 0.0% of revenue in FY2025.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Interest Expense vs competitors

How ATTO compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Interest expense amounts to 0.0% of revenue for ATTO, versus a peer median of 0.0%.
ATTO Competitors
Interest Expense for ATTO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANABAnaptysBio, Inc.LTM Mar 2026$82.69M USD+33.7%+55.8%35.6%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$9.5M USD+52672.2%——
QTTBQ32 Bio Inc.LTM Mar 2026$1M USD-56.5%—1.9%
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024€67K EUR+116.1%——
EVMNEvommune, Inc.LTM Mar 2026$3K USD——0.0%
ATTOAttovia Therapeutics, Inc.FY2025$0 USD——0.0%
ORKAOruka Therapeutics, Inc.LTM Sep 2026$0 USD———
ALMSAlumis Inc. Common StockLTM Jun 2026$0 USD——0.0%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
ZURAZura Bio LimitedLTM Mar 2026$0 USD———
CNTBConnect Biopharma Holdings LimitedFY2025$0 USD——0.0%
Peer median (excluding ATTO) —+74.9%+55.8%0.0%

Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2024
Dec 2024
FY2025
Dec 2025
Revenue01.35M
Cost of Revenue313K804K
Gross Profit(313K)546K
Gross Margin—40.4%
Research & Development33.86M54.15M
Selling, General & Admin7.38M13.55M
Operating Expenses41.24M67.71M
Depreciation & Amortization313K804K
EBITDA(41.24M)(66.36M)
EBITDA Margin—-4915.2%
Operating Income(41.55M)(67.16M)
Operating Margin—-4974.7%
Interest Income3.44M6.63M
Interest Expense00
Other Income / Expenses1.75M6.53M
Income Before Tax(39.8M)(60.63M)
Pre-Tax Margin—-4490.9%
Income Tax Expense00
Net Income(39.8M)(60.63M)
Net Margin—-4490.9%
EPS (Basic)(1.05)(1.42)
EPS (Diluted)(1.05)(1.42)
Weighted Avg Shares43.03M43.03M
Weighted Avg Shares (Diluted)43.03M43.03M

Attovia Therapeutics, Inc.

NASDAQ:ATTO

Intrinsic Alpha fair value

Locked

Current Price

$15.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.